

Special Issue

Recent Advances in Virus-Like Particle-Based Vaccines

Message from the Guest Editor

The first virus-like particle (VLP)-based vaccine, designed to combat the hepatitis B virus, marks a significant milestone in subunit vaccine development. Among the notable examples of VLPs successfully employed as human and animal health immunizing agents are the vaccines for human papillomavirus and porcine circovirus type 2. Beyond their role as vaccines, VLPs have the potential to function as scaffolds for the incorporation of short peptides and antigens, thereby enhancing their delivery system. This targeted approach allows for a focused strategy to concentrate on one or a select few antigens instead of overwhelming the immune response with a myriad of antigens. Moreover, VLPs can be strategically utilized to induce immune tolerance or robust immune responses against antigens that are over-expressed in cancer cells, presenting new avenues for cancer immunotherapy. Research areas of interest include, but are not limited to, the following:

- VLP Design and Antigen Engineering;
- Immune Response and Vaccine Delivery;
- Preclinical and Clinical Evaluation;
- Therapeutic Vaccines for Chronic Diseases;
- Rapid Vaccine Development for Emerging Pathogens.

Guest Editor

Dr. Abel Gutiérrez-Ortega

Centro de Investigación y Asistencia en Tecnología y Diseño del Estado de Jalisco, Mérida, México

Deadline for manuscript submissions

31 December 2025



Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



mdpi.com/si/234402

Vaccines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
vaccines@mdpi.com

[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)





Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)



About the Journal

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

Editor-in-Chief

Prof. Dr. Ralph A. Tripp

Department of Infectious Diseases, College of Veterinary Medicine,
University of Georgia, Athens, GA 30602-7387, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPIus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) /
CiteScore - Q1 (Pharmacology (medical))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 19.6 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the first half of 2025).